Your browser doesn't support javascript.
loading
Trilobatin promotes angiogenesis after cerebral ischemia-reperfusion injury via SIRT7/VEGFA signaling pathway in rats.
Huang, Fengying; Luo, Lingyu; Wu, Yujia; Xia, Dianya; Xu, Fan; Gao, Jianmei; Shi, Jingshan; Gong, Qihai.
Afiliação
  • Huang F; Key Laboratory of Basic Pharmacology of Ministry of Education and Guizhou Province, Zunyi Medical University, Zunyi, China.
  • Luo L; Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China.
  • Wu Y; Key Laboratory of Basic Pharmacology of Ministry of Education and Guizhou Province, Zunyi Medical University, Zunyi, China.
  • Xia D; Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China.
  • Xu F; Key Laboratory of Basic Pharmacology of Ministry of Education and Guizhou Province, Zunyi Medical University, Zunyi, China.
  • Gao J; Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China.
  • Shi J; Key Laboratory of Basic Pharmacology of Ministry of Education and Guizhou Province, Zunyi Medical University, Zunyi, China.
  • Gong Q; Joint International Research Laboratory of Ethnomedicine of Ministry of Education, Zunyi Medical University, Zunyi, China.
Phytother Res ; 36(7): 2940-2951, 2022 Jul.
Article em En | MEDLINE | ID: mdl-35537702

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Flavonoides / Traumatismo por Reperfusão / Sirtuínas / Polifenóis Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Phytother Res Assunto da revista: TERAPIAS COMPLEMENTARES Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Flavonoides / Traumatismo por Reperfusão / Sirtuínas / Polifenóis Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Phytother Res Assunto da revista: TERAPIAS COMPLEMENTARES Ano de publicação: 2022 Tipo de documento: Article País de afiliação: China